Ken Markus - Innovid Corp Chief Officer
| CTV Stock | USD 3.05 0.04 1.33% |
Insider
Ken Markus is Chief Officer of Innovid Corp
| Age | 49 |
| Address | 30 Irving Place, New York, NY, United States, 10003 |
| Phone | 212 966 7555 |
| Web | https://www.innovid.com |
Ken Markus Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ken Markus against Innovid Corp stock is an integral part of due diligence when investing in Innovid Corp. Ken Markus insider activity provides valuable insight into whether Innovid Corp is net buyers or sellers over its current business cycle. Note, Innovid Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Innovid Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ken Markus over a month ago Disposition of 2191 shares by Ken Markus of Innovid Corp at 1.6968 subject to Rule 16b-3 |
Innovid Corp Management Efficiency
The company has Return on Asset of (0.0257) % which means that on every $100 spent on assets, it lost $0.0257. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0702) %, meaning that it generated no profit with money invested by stockholders. Innovid Corp's management efficiency ratios could be used to measure how well Innovid Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.08 in 2024. At this time, Innovid Corp's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 106 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 74.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mitchell Walorski | CTS Corporation | N/A | |
| Anshuman Mehrotra | Belden Inc | 53 | |
| Jacques Theurillat | ADC Therapeutics SA | 62 | |
| Yelena Simonyuk | Comtech Telecommunications Corp | N/A | |
| Thomas Rinderknecht | ADC Therapeutics SA | 67 | |
| Thomas White | CTS Corporation | 38 | |
| Ye Li | CTS Corporation | 53 | |
| Joseph Camardo | ADC Therapeutics SA | 71 | |
| Ashish Chand | Belden Inc | 49 | |
| Susan Romanus | ADC Therapeutics SA | 59 | |
| Robert Samuels | Comtech Telecommunications Corp | N/A | |
| Lajuana Johnson | Comtech Telecommunications Corp | N/A | |
| Gregory McCray | Belden Inc | 57 | |
| Kimberly Pope | ADC Therapeutics SA | 57 | |
| Amanda Hamilton | ADC Therapeutics SA | N/A | |
| Richard Onyett | ADC Therapeutics SA | 73 | |
| Stephane Henchoz | ADC Therapeutics SA | N/A | |
| Kevin Maczka | Belden Inc | N/A | |
| Scott DAngelo | CTS Corporation | 53 | |
| Peter Greaney | ADC Therapeutics SA | 41 | |
| Lisa Skelton | ADC Therapeutics SA | 53 | |
Management Performance
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0257 |
Innovid Corp Leadership Team
Elected by the shareholders, the Innovid Corp's board of directors comprises two types of representatives: Innovid Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovid. The board's role is to monitor Innovid Corp's management team and ensure that shareholders' interests are well served. Innovid Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovid Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tanya AndreevKaspin, Executive Officer | ||
| Tim Braz, VP Sales | ||
| Stephanie Geno, Chief Officer | ||
| Stephen Cook, General Counsel | ||
| Ken Markus, Chief Officer | ||
| John Williams, Head Relations | ||
| Pr Netter, CEO CoFounder | ||
| Michal Livny, Senior Operations | ||
| Anthony Callini, Chief Officer | ||
| Dani Cushion, Chief Officer | ||
| David Helmreich, Chief Officer | ||
| Kenneth Markus, Chief Officer | ||
| Liel Golan, Senior Resources | ||
| Yuval Pemper, Chief Officer | ||
| Tal Chalozin, CoFounder CTO | ||
| Arik Shahar, VP Measurement | ||
| Guy Kuperman, Chief Officer |
Innovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innovid Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0702 | ||||
| Return On Asset | -0.0257 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 429.5 M | ||||
| Shares Outstanding | 148.47 M | ||||
| Shares Owned By Insiders | 13.21 % | ||||
| Shares Owned By Institutions | 55.92 % | ||||
| Number Of Shares Shorted | 1.31 M | ||||
| Price To Earning | 23.87 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Innovid Stock Analysis
When running Innovid Corp's price analysis, check to measure Innovid Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovid Corp is operating at the current time. Most of Innovid Corp's value examination focuses on studying past and present price action to predict the probability of Innovid Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovid Corp's price. Additionally, you may evaluate how the addition of Innovid Corp to your portfolios can decrease your overall portfolio volatility.